• 제목/요약/키워드: Endocrine hormone

검색결과 252건 처리시간 0.03초

Toxicological Mechanism of Endocrine Disrupting Chemicals: Is Estrogen Receptor Involved?

  • Jeung, Eui-Bae;Choi, Kyung-Chul
    • Toxicological Research
    • /
    • 제26권4호
    • /
    • pp.237-243
    • /
    • 2010
  • Endocrine disrupting chemicals (EDCs) have been shown to interfere with physiological systems, i.e., adversely affecting hormone balance (endocrine system), or disrupting normal function, in the female and male reproductive organs. Although endocrine disruption is a global concern for human health, its impact and significance and the screening strategy for detecting these synthetic or man-made chemicals are not clearly understood in female and male reproductive functions. Thus, in this review, we summarize the interference of environmental EDCs on reproductive development and function, and toxicological mechanism(s) of EDCs in in vitro and in vivo models of male and female reproductive system. In addition, this review highlights the effect of exposure to multiple EDCs on reproductive functions, and brings attention to their toxicological mechanism(s) through estrogen receptors.

내분비장애물질로서 Metribuzin의 랫드와 HeLaTRE Cell 중 갑상선 호르몬활성 영향 (Thyroid Hormone-like Activity of Metribuzin as a Endocrine Disruptor in Rats and HeLaTRE Cell Culture)

  • 유아선;정미혜;이제봉;박연기;신진섭;박경훈
    • 농약과학회지
    • /
    • 제12권4호
    • /
    • pp.342-350
    • /
    • 2008
  • 최근 내분비장애 추정물질의 분류를 위해 많은 시험법이 연구되고 있으며 미국 EPA와 OECD에서는 시험법을 설정하려고 노력하고 있다. 추후 기등록농약에 대한 자료요구 또는 신규 등록농약 적용 등록기준의 추가 등을 고려하여 내분비계장애 추정물질 관련 OECD와 EPA에서 권장하는 시험법을 확립하고자 본 연구를 수행하였다. 시험약제를 30일간 경구 투여하여 조사한 결과, metribuzin 투여 수컷에서 부고환, 전립선, 정낭의 중량이 증가하였고 갑상선에서는 유의한 중량변화가 나타나지 않았다. 암컷에서는 갑상선의 중량 감소가 나타난 반면에 생식장기 중량에는 유의적인 변화가 없었다. Metribuzin 투여수컷에서 testosterone이 100 mg/kg/day 처리수준에서 감소하였고 FT4가 50, 100 mg/kg 수준에서 증가하였다. 암컷에서는 T3가 50, 100 mg/kg/day 수준에서 증가하여 갑상선 호르몬에 영향이 나타나는 것을 볼 수 있었다. 시험세포를 이용한 시험결과, 시험약제를 1 nM에서 1,000 nM까지 처리하였을 때 음성대조군과 비교할 때 metribuzin은 106-122%의 영향을 나타내어 세포이용시험에서는 metribuzin이 갑상선 호르몬성 영향을 보인 것으로 나타났다. 항갑상선 호르몬성 영향 시험에서는 시험약제 100 nM과 T4의 혼합 처리시 metribuzin은 양성 대조군과 비교하여 감소하여 항갑상선 호르몬성 영향을 나타내었다. 본 시험을 통하여 OECD TG 407과 EDSTAC에서 권고하는 pubertal assay와 수의과학 검역원에서 제조한 HeLaTRE cell을 이용한 in vitro 시험이 갑상선 호르몬성 영향 검색 시험으로 활용될 가능성이 있는 것으로 사료되었다.

랫드와 HeLaTRE Cell에서의 Alachlor에 의한 갑상선 호르몬성 영향 연구 (Thyroid Hormone-like Activity of Alachlor as R Endocrine Disruptor in Rats and HeLaTRE Cell Culture)

  • 유아선;정미혜;박경훈;김병석;김진배;권오경
    • 농약과학회지
    • /
    • 제12권3호
    • /
    • pp.207-214
    • /
    • 2008
  • 내분비장애 추정물질의 분류를 위해 많은 시험법이 연구되고 있는데 추후 내분비장애 추정물질로 분류된 기등록 농약에 대한 자료요구 또는 신규 등록농약에 대한 등록기준의 추가 등을 고려하여 OECD와 EPA에서 권장하는 시험법을 확립하고자 본 연구를 수행하였다. 시험약제를 30일간 경구 투여하여 조사한 결과, alachlor 투여 수컷에서 25 mg/kg/day, 50 mg/kg/day에서 고환과 갑성선의 중량이 증가하였다. Alachlor 투여 암컷에서는 질의 중량이 25, 50 mg/kg/day에서 감소하였고 25 mg/kg/day에서 갑상선의 중량이 감소하였다. Alachlor 투여 암컷 25, 50 mg/kg/day에서 주요 갑상선 호르몬인 T4와 성호르몬 testosterone이 감소하였다. 따라서 pubertal assay 결과 alachlor는 갑상선 호르몬성 영향이 의심되었다. 시험세포를 이용한 시험 결과, 시험약제를 1 nM에서 1000 nM까지 처리하였을 때 음성대조군과 비교하여 alachlor는 100-134%의 갑상선 호르몬성 영향을 나타내었다. 따라서 세포를 이용한 시험에서는 alachlor에 의한 갑상선 호르몬성 영향이 나타나는 것으로 판단되었다. 항갑상선 호르몬성 영향 시험에서는 시험약제 100 nM과 T4의 혼합 처리시 alachlor는 항갑상선 호르몬성 영향은 나타나지 않았다.

Growth Hormone Therapy in Children with Prader-Willi Syndrome

  • Im, Minji
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제5권1호
    • /
    • pp.34-38
    • /
    • 2021
  • Prader-Willi syndrome is a complicated genetic disorder caused by a mutation on chromosome 15q11-13. The disease results in morbid obesity due to hyperphagia, growth disturbance, multiple endocrine problems from hypopituitarism, developmental delay, and cognitive or behavioral problems. Recombinant human growth hormone has been used to improve body composition and muscle mass, which plays a main role in treating patients with Prader-Willi syndrome. We describe previous studies showing the efficacy and safety of growth hormone treatment in children with Prader-Willi syndrome and provide treatment guidelines. Growth hormone therapy could be beneficial for children with Prader-Willi syndrome and improve their quality of life.

EID-1 Interacts with Orphan Nuclear Receptor SF-1 and Represses Its Transactivation

  • Park, Yun-Yong;Park, Ki Cheol;Shong, Minho;Lee, Soon-Jung;Lee, Young-Ho;Choi, Hueng-Sik
    • Molecules and Cells
    • /
    • 제24권3호
    • /
    • pp.372-377
    • /
    • 2007
  • The orphan nuclear receptor, SF-1, plays a pivotal role in the development and differentiation of the endocrine and reproductive systems, and also regulates the transcription of a host of genes, including those encoding several steroidogenic enzymes and gonadotropins. We found that a previously unidentified repressor, EID-1, is an SF-1-interacting protein that inhibits the transactivation of SF-1. A transient transfection assay revealed that EID-1 inhibits SF-1, but not LRH-1, $ERR{\gamma}$, or mCAR. Using the yeast two hybrid and GST pull-down assays, we determined that EID-1 interacted strongly with SF-1. In addition, it colocalized with SF-1 in mammalian cells and interacted specifically with the AF-2 domain of SF-1, competing with SRC-1 to inhibit SF-1 transactivation. EID-1 is expressed in the mouse testis, and its expression decreases during testis development. The results of the present study suggest that EID-1 can act as a repressor, regulating the function of SF-1.

Safety effect of fermented oyster extract on the endocrine disruptor assay in vitro and in vivo

  • Lee, Hyesook;Hwangbo, Hyun;Ji, Seon Yeong;Oh, Seyeon;Byun, Kyung-A;Park, Joung-Hyun;Lee, Bae-Jin;Kim, Gi-Young;Choi, Yung Hyun
    • Fisheries and Aquatic Sciences
    • /
    • 제24권10호
    • /
    • pp.330-339
    • /
    • 2021
  • Oyster (Crassostrea gigas) is a marine bivalve mollusk widely distributed in coastal areas, and have been long widely used in industrial resources. Several studies demonstrated that fermented oyster (FO) extract attribute to bone health, but whether administration of FO play as an endocrine disruptor has not been studied. Therefore, in the present study, we investigated the effect of FO on the endocrine system in vitro and in vivo. As the results of the competitive estrogen receptor (ER) and androgen receptor (AR) binding affinities, FO was not combined with ER-α, ER-β, and AR. However, 17β-estradiol and testosterone, used as positive control, were interacted with ER and AR, respectively. Meanwhile, oral administration of 100 mg/kg and 200 mg/kg of FO doesn't have any harmful effect on the body weight, androgen-dependent sex accessory organs, estrogen-dependent-sex accessory organs, kidney, and liver in immature rats. In addition, FO supplementation has no effect on the serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, and 17β-estradiol. However, the relative weight of androgen- and estrogen-dependent organs were significantly increased by subcutaneously injection of 4.0 mg/kg of testosterone propionate (TP) and by orally administration of 1.0 ㎍ of 17α-ethynyl estradiol (EE) in immature male and female rats, respectively. Furthermore, TP and EE administration markedly decreased the serum LH and FSH levels, which are similar those of mature Sprague-Dawley (SD) rat. Furthermore, the testosterone and 17β-estradiol levels were significantly enhanced in TP and EE-treated immature rats. Taken together, our findings showed that FO does not interact with ER and AR, suggesting consequentially FO does not play as a ligand for ER and AR. Furthermore, oral administration of FO did not act as an endocrine disruptor including androgenic activity, estrogenic activity, and abnormal levels of sex hormone, indicating FO may ensure the safety on endocrine system to develop dietary supplement for bone health.

호르몬수면상실이 에너지와 대사에 미치는 영향 (The Effect of Sleep Loss on Energy and Metabolism)

  • 강승걸
    • 수면정신생리
    • /
    • 제19권1호
    • /
    • pp.5-10
    • /
    • 2012
  • The release of hormones and the metabolism of human body are controlled by the circadian rhythm related to sleep-wake cycle. Growth hormone, prolactin, thyroid stimulating hormone, cortisol, glucose, and insulin-secretion rates fluctuate according to the sleep-wake cycle. In addition, sleep is related to the appetite regulation and carbohydrate and other energy metabolism. Hypocretin (orexin), an excitatory neuropeptide, regulates waking and diet intake, and the poor sleep increases diet intake. The short sleep duration increases one's body mass index and impairs the function of the endocrine and metabolism, causing increases in the risk of glucose intolerance and diabetes. The poor sleep quality and sleep disorders have similar impact on the metabolic function. In short, the sleep loss and the poor quality of sleep have a detrimental effect on the endocrine and energy metabolism. The improvement of sleep quality by the future research and appropriate clinical treatment would contribute to the decrease of the metabolic diseases such as diabetes.

The Endocrine Regulation of Chicken Growth

  • Kim, Jin-Wook
    • Asian-Australasian Journal of Animal Sciences
    • /
    • 제23권12호
    • /
    • pp.1668-1676
    • /
    • 2010
  • The somatotropic axis plays a key role in proliferation and differentiation of avian organs during both pre- and posthatching periods. This review discusses the complexity of regulation of the endocrine system for chicken development and growth by growth hormone (GH), insulin-like growth factor (IGF), and IGF binding protein (IGFBP). In addition, the thyrotropic axis, including thyrotropin-releasing hormone (TRH) and thyroid hormones ($T_4$ and $T_3$), is also involved in the GH-secreting pattern. In mammals, IGFI and -II are always sequestered in a 150 kDa non-covalent ternary complex. This complex consists of one molecule each of IGF-I or IGF-II, IGFBP-3 or IGFBP-5 and an acid labile subunit (ALS). Chick ALS is identified in different strains for the first time, and further investigation of the expression of ALS on developmental stage and ALS effect on IGF bioavailability may be addressed in the future.

Clinical Management of Gastric Neuroendocrine Tumors

  • In Kyung Yoo;Bora Keum
    • Journal of Digestive Cancer Research
    • /
    • 제3권1호
    • /
    • pp.21-25
    • /
    • 2015
  • Gastric neuroendocrine tumors (GNETs, also known as gastric carcinoids) are rare form of hormone-secreting neoplasms that present with varied clinical syndromes. There are four types of GNETs based on size, proliferation, localization, differentiation, and hormone production. Type I GNET is related to autoimmune atrophic gastritis and hypergastrinemia. Type II GNETs are related to multiple endocrine neoplasia (MEN)-1, Zollinger-Ellison syndrome and hypergastrinemia. Type 3 GNETs are not associated with any background pathology, and type 4 GNETs are poorly differentiated tumors. The most useful diagnostic and prognostic marker for gastrointestinal NETs is plasma chromogranin A (CgA) levels. Endoscopic ultrasound is the method of choice to determine tumor size and depth of infiltration. For optimal management, the type, biology, and stage of the tumor must be considered. Here, we provide a comprehensive and up-to-date review of GNETs.

  • PDF